S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

AUTL Autolus Therapeutics PLC

2.765

-0.135 (-4.66%)

Last Updated: 10:47:10

Delayed by 15 minutes

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

null

Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Nov 2024 to Dec 2024

Click Here for more Autolus Therapeutics Charts.

Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Dec 2023 to Dec 2024

Click Here for more Autolus Therapeutics Charts.

Autolus Therapeutics PLC News

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
Monday 9 December 2024 (3 days ago) • GlobeNewswire Inc.

Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine
Monday 2 December 2024 (1 week ago) • GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Thursday 14 November 2024 (4 weeks ago) • Edgar (US Regulatory)

Form S-8 - Securities to be offered to employees in employee benefit plans
Thursday 14 November 2024 (4 weeks ago) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Thursday 14 November 2024 (4 weeks ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Tuesday 12 November 2024 (4 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Tuesday 12 November 2024 (1 month ago) • Edgar (US Regulatory)

Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
Tuesday 12 November 2024 (1 month ago) • GlobeNewswire Inc.

Form 8-K - Current report
Tuesday 12 November 2024 (1 month ago) • Edgar (US Regulatory)

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
Friday 8 November 2024 (1 month ago) • GlobeNewswire Inc.

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations
Tuesday 5 November 2024 (1 month ago) • GlobeNewswire Inc.

Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
Monday 28 October 2024 (1 month ago) • GlobeNewswire Inc.

More Autolus Therapeutics PLC News Articles

BNP Paribas Issuance

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions